Nice’s decision to deny NHS coverage for Lecanemab contrasts with MHRA’s approval, citing high costs and minimal benefits compared to risks of serious side-effects
Voxelotor, a promising new drug for sickle cell disease, will be made available to patients in england, aiming to reduce hospital visits and improve life quality.